GSK Depemokimab accepted for review by EMA for use in asthma with type 2 inflammation, CRSwNP Ruchika Sharma29 Jan 2025 2:30 PM ISTLondon: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for...
Depemokimab reduces exacerbations in patients with severe asthma with eosinophilic phenotype, reveals study Dr.Niharika Harsha B27 Dec 2024 9:15 PM ISTA recent novel study published in the New England Journal of Medicine found that Depemokimab can reduce asthma exacerbations in patients with the...
USFDA accepts GSK submission for use of Nucala in COPD Ruchika Sharma11 Dec 2024 11:30 AM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the...
Twice-Yearly Depemokimab Effectively Lowers Exacerbation Rates in Severe Eosinophilic Asthma: Study Reveals Medha Baranwal13 Oct 2024 8:30 PM ISTUSA: A recent study published in the New England Journal of Medicine highlights the effectiveness of Depemokimab, an innovative monoclonal antibody,...
Sanofi, Regeneron get USFDA nod for Dupixent for COPD Ruchika Sharma29 Sept 2024 12:30 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment...
